Literature DB >> 16100112

Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase.

Hua Wei1, Alexander J Ruthenburg, Seth K Bechis, Gregory L Verdine.   

Abstract

Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topological state, chromosome segregation, and chromatin condensation. These diverse physiologic functions are all accomplished through a common molecular mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed. The overall process is orchestrated by the opening and closing of molecular "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorganic phosphate. Here we present two crystal structures of the ATPase domain of human DNA topoisomerase IIalpha in different nucleotide-bound states. Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a molecular gate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100112     DOI: 10.1074/jbc.M506520200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry.

Authors:  Yu-Tsung Chen; Tammy R L Collins; Ziqiang Guan; Vincent B Chen; Tao-Shih Hsieh
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

2.  Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.

Authors:  Yi Ma; Jian-Guo Wang; Bin Wang; Zheng-Ming Li
Journal:  J Mol Model       Date:  2010-11-25       Impact factor: 1.810

Review 3.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

4.  E. coli Gyrase Fails to Negatively Supercoil Diaminopurine-Substituted DNA.

Authors:  Mónica Fernández-Sierra; Qing Shao; Chandler Fountain; Laura Finzi; David Dunlap
Journal:  J Mol Biol       Date:  2015-04-19       Impact factor: 5.469

5.  Dynamics of strand passage catalyzed by topoisomerase II.

Authors:  Ping Xie
Journal:  Eur Biophys J       Date:  2010-02-03       Impact factor: 1.733

6.  Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate.

Authors:  Nuri Sung; Jungsoon Lee; Ji-Hyun Kim; Changsoo Chang; Andrzej Joachimiak; Sukyeong Lee; Francis T F Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

7.  Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy.

Authors:  Elizabeth A Williamson; Leah Damiani; Andrei Leitao; Chelin Hu; Helen Hathaway; Tudor Oprea; Larry Sklar; Montaser Shaheen; Julie Bauman; Wei Wang; Jac A Nickoloff; Suk-Hee Lee; Robert Hromas
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

8.  Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.

Authors:  Caitlin E Cassidy; William N Setzer
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

9.  Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.

Authors:  Bo Xu; Ling Wang; Lorenzo González-Molleda; Yan Wang; Jun Xu; Yan Yuan
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors:  Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.